Not Accepting Cases

NuvaRing Side Effects

NuvaRing is a popular combination hormone contraceptive (CHC) like birth control pills and patches. But a series of studies have identified increased risks for serious and potentially fatal side effects associated with the novel birth control ring.

Erika Langhart had traveled to 37 countries and served on the staff of a presidential nominee before even graduating college. Just before Thanksgiving 2011, her boyfriend came home to find the young law student on the floor of their apartment in extreme pain.

Paramedics were already on the way, but Langhart suffered two heart attacks before they got her to the hospital and slipped into a coma. She died on Thanksgiving Day. Langhart was 24 years old.

One of the first questions the emergency room doctor asked family members was if Langhart was using birth control. When her mother, Karen, said Erika had been using NuvaRing, the doctor told her of a link between the contraceptive and pulmonary embolisms.

These deadly blood clots are among the most serious risks associated with the popular NuvaRing birth control ring. Warnings of the risks would not be added to NuvaRing’s label until almost two years after Langhart’s death.

Timeline: Rising Popularity, Increased Risks

  • October 2001
    FDA approves NuvaRing
  • 2010
    6 percent of U.S. women who have used birth control in the previous four years report having used NuvaRing
  • 2011
    FDA-funded study of 835,826 women finds “increased risk of VTE” among NuvaRing users
  • 2012
    759,000 women surveyed in the U.S. report having used NuvaRing in the previous month
  • May 2012
    Study finds 6.5 times higher risk of VTE for NuvaRing compared to other hormonal birth control
  • June 2012
    Study finds increased heart attack and stroke risk
  • October 2013
    FDA approves NuvaRing label warning for VTE and other vascular risks

Convenience, Potentially Dangerous Side Effects

NuvaRing package
NuvaRing package

Despite the label warnings added in 2013 that include a risk of “thromboembolic events,” NuvaRing remains a popular contraceptive choice because it is convenient and effective.

It is inserted in the vagina once a month and only IUDs and injectable contraceptives have better rates of preventing pregnancy when used as directed. NuvaRing’s effectiveness is equal to birth control pills and patches.

NuvaRing, like the patch and pill, is a combined hormonal contraceptive (CHC) — a combination of estrogen and progestin. The use of any CHC increases the risk of a venous thromboembolism (VTE) — a blood clot that begins in a vein.

There are two types of VTEs:
Deep vein thrombosis (DVT)
DVT is a blood clot that usually forms in the leg but may form in the arms or veins in other parts of the body.
Pulmonary embolism (PE)
PE happens when a DVT clot breaks free and travels to the lung, blocking blood flow — with potentially fatal results. These clots usually form in the thigh.

VTEs are life-threatening conditions. If you suspect you have either a DVT or a PE, you should seek immediate medical attention.

What Are the Symptoms of DVT?

DVT usually affects the lower leg or thigh, and most often occur only on one side of the body.

deep vein thrombosis (DVT) in leg and thigh
Deep vein thrombosis (DVT) in leg and thigh
Symptoms of DVT include:
  • Thigh or calf tenderness
  • Leg pain
  • Reddish discoloration
  • Edema – leg swelling
  • Skin is warm to the touch
  • Red streaks on the leg

What Are the Symptoms of PE?

PE can be a fatal result of a blood clot in the leg breaking free and reaching the lungs.

Symptoms of PE include:
  • Unexplained shortness of breath
  • Fast heart rate
  • Lightheadedness
  • Chest pain beneath the rib cage
  • Rapid breathing
  • Fainting

While smoking, obesity, and a family history of VTE can increase the risk for women using a CHC, several studies have found an association between one of the hormones in NuvaRing, etonogestrel, and a higher risk of VTE than that of birth control pills. Some studies found the risk of VTE for NuvaRing users was almost double that of women using oral contraceptives.

Studies: NuvaRing Poses Cardiovascular Risks

In October 2011, the U.S. Food and Drug Administration (FDA) released a study of more than 835,826 women that found use of NuvaRing was “associated with a significantly higher risk of VTE” compared to low-dose oral contraceptives. The authors said the finding was “new and raises concern” and called for further studies.

Another study published in May 2012, which followed more than 1.6 million Danish women from 2001 to 2010, was “compatible with the [FDA] study,” in the words of its authors. The 2012 study included data on “all Danish non-pregnant women aged 15-49” who were “free of previous thrombotic disease or cancer.”

Researchers found that “vaginal rings increased the risk of venous thrombosis 6.5 times compared with non-use of hormonal contraception.”

“[NuvaRing] conferred a 90 percent higher risk of blood clots than oral contraceptives containing levonorgestrel.”

Denmark researchers, May 2012

In June 2012, the New England Journal of Medicine published another Danish study based on 15 years of data. This study found increased risks of myocardial infarctions (heart attacks) and thrombotic strokes.

“Our data suggest a relatively high risk of thrombotic stroke with the use of a vaginal ring and possibly with the use of transdermal patches,” the researchers wrote.

In October 2013, the FDA approved new warnings for NuvaRing’s label.

NuvaRing’s warning label says:
  • Stop using NuvaRing if a thrombotic event occurs
  • Use of CHCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events
  • Use NuvaRing with caution in women with cardiovascular disease risk factors

By this time, court documents showed hundreds of women in the U.S. had suffered VTEs or other serious complications while using NuvaRing.

Other NuvaRing Complications

NuvaRing’s label lists other warnings and precautions of possible conditions women may experience.

Side Effect Description Symptoms
Toxic shock syndrome A serious disease caused by staphylococcus bacteria involving fever, shock and problems with several organs Confusion, diarrhea, headaches, high fever, chills, low blood pressure, muscle aches, nausea vomiting, organ failure, redness of eyes, mouth, and throat, sunburn-like rash, seizures
Liver disease Liver function may be disrupted, liver tumors called hepatic adenomas may burst causing potentially fatal bleeding, and long-term use can increase risk of certain liver cancers Jaundice, pain or mass in abdomen
High Blood Pressure An increase in high blood pressure has been reported by women using CHCs. This risk increases with age. It can result in stroke, heart failure, heart attack, and kidney failure Symptoms do not usually appear until the body is damaged from chronic high blood pressure
Headaches Women who experience new, more frequent, severe headaches should consult their doctor while using NuvaRing New, recurring, persistent, or severe headaches
Uterine bleeding Unscheduled bleeding may occur with users of CHCs in the first three months of use. If this persists beyond three months while using NuvaRing, you should talk to your doctor Unscheduled bleeding and spotting
Amenorrhea Lack of a scheduled period while using NuvaRing — this may indicate pregnancy Failure to experience a period on schedule
Oligomenorrhea Infrequent periods Periods occur more than 35 days apart

Who Should Not Use NuvaRing?

Women with certain medical conditions or characteristics should not use NuvaRing.

Women who should not use NuvaRing include:
  • Smoke and are over the age of 35
  • Have a high risk of arterial or venous thrombotic diseases
  • Have liver tumors or liver disease
  • Have undiagnosed abnormal uterine bleeding
  • Are pregnant
  • Have or have had breast cancer or other cancers sensitive to estrogen or progestin
  • Have a hypersensitivity to any NuvaRing component

You should let your doctor know if you meet any of these conditions when discussing NuvaRing.

NuvaRing: Symptoms You Should Contact Your Doctor About

The National Institutes of Health recommends you talk to your doctor immediately if you experience any of these symptoms while using NuvaRing.

  • Pain in back of lower leg
  • Sharp, sudden, or crushing chest pain
  • Heaviness in chest
  • Coughing up blood
  • Swelling of the hands, feet, ankles, or lower legs
Stroke or heart attack
  • Sudden shortness of breath
  • Sudden severe headache, vomiting, dizziness or fainting
  • Sudden problems with speech
  • Weakness or numbness of an arm or leg
  • Sudden loss of vision or other changes in vision
  • Bulging eyes
Liver or gallbladder disorder
  • Yellowing of the skin or eyes
  • Pain, tenderness, or swelling of the abdomen
  • Stomach pain that worsens after eating
  • Depression
  • Trouble sleeping
  • Tiredness
  • Loss of energy
  • Mood swings
Toxic shock syndrome
  • Diarrhea
  • Sunburn-like rash — skin peeling occurs one or two weeks after the rash, particularly on the palms of the hand or bottom of feet
  • Painful, difficult, or frequent urination

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Medically Reviewed By
Dr. Joseph Palermo
Dr. Joseph Palermo Osteopathic Medicine

14 Cited Research Articles

  1. Kaye, R. and Shepherd, S. (2015, April 7). Families, Lawsuits, Raise Questions about NuvaRing. Retrieved from:
  2. Karlsson, J. and Brenner, M. (2014, January). Danger in the Ring. Retrieved from:
  3. American Heart Association. (2017, March 9). Symptoms and Diagnosis of Venous Thromboembolism (VTE). Retrieved from:
  4. FDA. (2013, October). NuvaRing Label. Retrieved from:
  5. Guttmacher Institute. (2016, September). Contraceptive Use in the United States. Retrieved from:
  6. FDA. (2011). Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints (pg. 6-7). Retrieved from:
  7. Lidegaard, Ø., et al. (2012, May 10). Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-up Study, Denmark 2001-10. Retrieved from:
  8. Lidegaard, Ø., et al. (2012, June 14). Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception. Retrieved from:
  9. NIH. (2016, April 12). Toxic Shock Syndrome. Retrieved from:
  10. NIH. (n.d.). High Blood Pressure. Retrieved from:
  11. NIH. (n.d.). Amenorrhea: Overview. Retrieved from:
  12. NIH. (n.d.). What Are Menstrual Irregularities? Retrieved from:
  13. UCSF Medical Center. (n.d.). Stroke Signs and Symptoms. Retrieved from:
  14. Herrine, S.K. (n.d.). Jaundice in Adults. Retrieved from:
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(888) 645-1617

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.